New combo approach targets insomnia in veterans with PTSD

NCT ID NCT03937713

Completed Symptom relief Sponsor: VA Office of Research and Development Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether adding the sleep medication eszopiclone (Lunesta) to brief behavioral therapy improves sleep quality and CPAP use in veterans with PTSD and complex insomnia. Fifty-three veterans who had trouble sticking with CPAP therapy for sleep apnea took part. The goal was to see if the combination helps them sleep better and manage PTSD symptoms.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: eszopiclone (Lunesta)
What this could lead to: If successful, this could point toward a better way to improve sleep and CPAP use in veterans with PTSD and insomnia.
What could go wrong: This is a small, completed Phase 4 trial with only 53 participants, so results may not apply broadly. The drug eszopiclone can cause side effects like drowsiness or dizziness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COMPLEX INSOMNIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

insomnia obstructive sleep apnea syndrome post-traumatic stress disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COMPLEX INSOMNIA

Contacts and locations

Locations

VA Western New York Healthcare System, Buffalo, NY

Buffalo, New York, 14215-1129, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.